QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 0.4048
-- x --
-- x --
-- - --
$ 0.20 - $ 0.49
13,473
na
1.78M
$ -0.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-23-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-02-2021 09-30-2021 10-Q
11 07-26-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 03-01-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-11-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 02-20-2020 12-31-2019 10-K
18 10-28-2019 09-30-2019 10-Q
19 08-01-2019 06-30-2019 10-Q
20 05-03-2019 03-31-2019 10-Q
21 03-12-2019 12-31-2018 10-K
22 11-02-2018 09-30-2018 10-Q
23 08-03-2018 06-30-2018 10-Q
24 05-07-2018 03-31-2018 10-Q
25 03-12-2018 12-31-2017 10-K
26 11-06-2017 09-30-2017 10-Q
27 07-28-2017 06-30-2017 10-Q
28 05-08-2017 03-31-2017 10-Q
29 03-15-2017 12-31-2016 10-K
30 11-07-2016 09-30-2016 10-Q
31 08-08-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 03-09-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
36 05-12-2015 03-31-2015 10-Q
37 03-26-2015 12-31-2014 10-K
38 11-13-2014 09-30-2014 10-Q
39 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 agile-therapeutics-q4-adj-146-misses-092-estimate-sales-362m-miss-407m-estimate

Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of ...

 why-agile-therapeutics-agrx-stock-is-down-60

Agile Therapeutics shares are trading lower by 61% during Tuesday's session. The company announced the suspension of its tr...

 agile-therapeutics-reveals-final-delisting-notice-from-nasdaq

Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on Marc...

 earnings-scheduled-for-march-22-2024

Companies Reporting Before The Bell • Agile Therapeutics (NASDAQ:AGRX) is likely to report quarterly loss at $0.54 per share o...

 maxim-group-downgrades-agile-therapeutics-to-hold

Maxim Group analyst Naz Rahman downgrades Agile Therapeutics (NASDAQ:AGRX) from Buy to Hold.

Core News & Articles

https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/

 why-etsy-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Etsy, Inc.

 whats-going-on-with-women-health-focused-agile-therapeutics-stock-today

Agile Therapeutics stock rises on premarket trading, exercising warrants for $4.8M gross proceeds with reduced exercise price o...

 why-nvidia-shares-are-trading-higher-by-around-14-here-are-20-stocks-moving-premarket

Shares of NVIDIA Corporation (NASDAQ: NVDA) rose sharply in today’s pre-market trading after the company reported better-than-...

 agile-therapeutics-announces-extension-granted-by-nasdaq-hearings-panel-to-regain-compliance-until-march-25-2024-sees-fy23-revenue-20m-21m

Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Req...

 the-biden-harris-administration-announces-new-guidance-to-enable-expanded-access-to-all-fda-approved-contraceptives-without-cost

Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Wo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION